Han N - Search Results

1

Prognostic implication of TSC1 and mTOR expression in gastric carcinoma.

Byeon SJ, Han N, Choi J, Kim MA, Kim WH. Byeon SJ, et al. Among authors: han n. J Surg Oncol. 2014 Jun;109(8):812-7. doi: 10.1002/jso.23585. Epub 2014 Feb 26. J Surg Oncol. 2014. PMID: 24615476

2

Caveolin 1 expression correlates with poor prognosis and focal adhesion kinase expression in gastric cancer.

Nam KH, Lee BL, Park JH, Kim J, Han N, Lee HE, Kim MA, Lee HS, Kim WH. Nam KH, et al. Among authors: han n. Pathobiology. 2013;80(2):87-94. doi: 10.1159/000341685. Epub 2012 Oct 3. Pathobiology. 2013. PMID: 23038627 Free article.

3

DNA damage response-related proteins in gastric cancer: ATM, Chk2 and p53 expression and their prognostic value.

Lee HE, Han N, Kim MA, Lee HS, Yang HK, Lee BL, Kim WH. Lee HE, et al. Among authors: han n. Pathobiology. 2014;81(1):25-35. doi: 10.1159/000351072. Epub 2013 Aug 21. Pathobiology. 2014. PMID: 23969480 Free article.

4

Loss of ARID1A Expression is Related to Gastric Cancer Progression, Epstein-Barr Virus Infection, and Mismatch Repair Deficiency.

Han N, Kim MA, Lee HS, Kim WH. Han N, et al. Appl Immunohistochem Mol Morphol. 2016 May-Jun;24(5):320-5. doi: 10.1097/PAI.0000000000000199. Appl Immunohistochem Mol Morphol. 2016. PMID: 26067140

5

Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer.

Han N, Kim MA, Lee HS, Kim WH. Han N, et al. Pathobiology. 2015;82(6):269-79. doi: 10.1159/000441149. Epub 2015 Oct 31. Pathobiology. 2015. PMID: 26516773 Free article.

6

WITHDRAWN:Uterine Arteriovenous Malformation Accompanied with a Uterine Stromomyoma.

Chung YR, Kwon D, Kim S, Na HY, Han N, Kim HJ, Kim MA, Park IA. Chung YR, et al. Among authors: han n. J Pathol Transl Med. 2017 Aug 4. doi: 10.4132/jptm.2016.09.24. Online ahead of print. J Pathol Transl Med. 2017. PMID: 28772353 Free article.

7

Evaluation of Intratumoral and Intertumoral Heterogeneity of MET Protein Expression in Gastric Cancer.

Choi J, Lee HE, Lee HS, Han N, Kim MA, Kim WH. Choi J, et al. Among authors: han n. Appl Immunohistochem Mol Morphol. 2018 Aug;26(7):445-453. doi: 10.1097/PAI.0000000000000448. Appl Immunohistochem Mol Morphol. 2018. PMID: 28968267 Clinical Trial.

8

Development and clinical application of an evidence-based pharmaceutical care service algorithm in acute coronary syndrome.

Kang JE, Yu JM, Choi JH, Chung IM, Pyun WB, Kim SA, Lee EK, Han NY, Yoon JH, Oh JM, Rhie SJ. Kang JE, et al. Among authors: han ny. J Clin Pharm Ther. 2018 Jun;43(3):366-376. doi: 10.1111/jcpt.12665. Epub 2018 Feb 21. J Clin Pharm Ther. 2018. PMID: 29468708 Clinical Trial.

9

Copy number variability analysis of pharmacogenes in patients with lymphoma, leukemia, hepatocellular, and lung carcinoma using The Cancer Genome Atlas data.

Kim IW, Han N, Kim MG, Kim T, Oh JM. Kim IW, et al. Among authors: han n. Pharmacogenet Genomics. 2015 Jan;25(1):1-7. doi: 10.1097/FPC.0000000000000097. Pharmacogenet Genomics. 2015. PMID: 25379720

10

The expression of tumor necrosis factor receptor 2 is correlated with the prognosis of cancer: a systematic review and meta-analysis.

Koh HM, Han N. Koh HM, et al. Among authors: han n. Transl Cancer Res. 2024 Aug 31;13(8):4231-4241. doi: 10.21037/tcr-24-275. Epub 2024 Aug 6. Transl Cancer Res. 2024. PMID: 39262483 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,330 results

Search Page

Filters